8 [15] M. Morigi, D. Macconi, C. Zoja et al., “Protein overload- induced NF-κB activation in proximal tubular cells requires HO through a PKC-dependent pathway,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1179–1189, 2002. [16] K. Basnayake, W.-Z. Ying, P.-X. Wang, and P. W. Sanders, “Immunoglobulin light chains activate tubular epithelial cells through redox signaling,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1165–1173, 2010. [17] M. Li, K. S. Hering-Smith, E. E. Simon, and V. Batu- man, “Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 860– 870, 2008. [18] P. W. Sanders, G. A. Herrera, A. Chen et al., “Diﬀerential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo,” Journal of Clinical Investigation, vol. 82, no. 6, pp. 2086–2096, 1988. [19] E. A. Johns, R. Turner, E. H. Cooper, and I. C. M. MacLennan, “Isoelectric points of urinary light chains in myelomatosis: analysis in relation to nephrotoxicity,” Journal of Clinical Pathology, vol. 39, no. 8, pp. 833–837, 1986. [20] M. D. Holland, J. H. Galla, P. W. Sanders, and R. G. Luke, “Eﬀect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat,” Kidney International, vol. 27, no. 1, pp. 46–50, 1985. [21] K. R. Porter and I. Tamm, “Direct visualization of a mucopro- tein component of urine,” The Journal of biological chemistry, vol. 212, no. 1, pp. 135–140, 1955. [22] R. Patel, J. K. Mckenzie, and E. G. Mcqueen, “Tamm-Horsfall urinary mucoprotein and tubular obstruction by cast in acute renal failure,” The Lancet, vol. 283, no. 7331, pp. 457–461, 1964. [23] Z. Q. Huang, K. A. Kirk, K. G. Connelly, and P. W. Sanders, “Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggrega- tion,” Journal of Clinical Investigation, vol. 92, no. 6, pp. 2975– 2983, 1993. [24] Z. Q. Huang and P. W. Sanders, “Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy,” Laboratory Investigation, vol. 73, no. 6, pp. 810–817, 1995. [25] S. J. Su, K. L. Chang, T. M. Lin, Y. H. Huang, and T. M. Yeh, “Uromodulin and Tamm Horsfall protein induce human monocytes to secrete TNF and express tissue factor,” Journal of Immunology, vol. 158, no. 7, pp. 3449–3456, 1997. [26] B. Kreft, W. J. Jabs, T. Laskay et al., “Polarized expression of Tamm-Horsfall protein by renal tubular epithelial cells activates human granulocytes,” Infection and Immunity, vol. 70, no. 5, pp. 2650–2656, 2002. [27] C. A. Hutchison, A. R. Bradwell, M. Cook et al., “Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-oﬀ hemodialysis,” Clin- ical Journal of the American Society of Nephrology, vol. 4, no. 4, pp. 745–754, 2009. [28] N. Leung, M. A. Gertz, S. R. Zeldenrust et al., “Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains,” Kidney International, vol. 73, no. 11, pp. 1282–1288, 2008. [29] R. Alexanian, M. A. Dimopoulos, K. Delasalle, and B. Barlogie, “Primary dexamethasone treatment of multiple myeloma,” Blood, vol. 80, no. 4, pp. 887–890, 1992. Bone Marrow Research [30] M. A. Dimopoulos, E. Terpos, A. Chanan-Khan et al., “Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4976– 4984, 2010. [31] J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. [32] U. Klein, K. Neben, T. Hielscher, C. Heiß, A. D. Ho, and H. Goldschmidt, “Lenalidomide in combination with dexamethasone: eﬀective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impair- ment,” Annals of Hematology, vol. 90, no. 4, pp. 429–439, 2011. [33] A. A. Chanan-Khan, J. L. Kaufman, J. Mehta et al., “Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study,” Blood, vol. 109, no. 6, pp. 2604–2606, 2007. [34] E. Kastritis, A. Anagnostopoulos, M. Roussou et al., “Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone- containing regimens and the impact of novel agents,” Haema- tologica, vol. 92, no. 4, pp. 546–549, 2007. [35] F. Morabito, M. Gentile, S. Ciolli et al., “Safety and eﬃ- cacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA,” European Journal of Haematology, vol. 84, no. 3, pp. 223–228, 2010. [36] H. Ludwig, J. Drach, H. Graf, A. Lang, and J. G. Meran, “Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma,” Haemato- logica, vol. 92, no. 10, pp. 1411–1414, 2007. [37] H. Ludwig, Z. Adam, R. Hajek et al., “Light chain- induced acute renal failure can be reversed by bortezomib- doxorubicin-dexamethasone in multiple myeloma: results of a phase II study,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4635–4641, 2010. [38] P. Tosi, E. Zamagni, C. Cellini et al., “Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure,” European Journal of Haematology, vol. 73, no. 2, pp. 98–103, 2004. [39] M. A. Dimopoulos, D. Christoulas, M. Roussou et al., “Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and eﬀect on renal impairment,” European Journal of Haematology, vol. 85, no. 1, pp. 1–5, 2010. [40] M. Dimopoulos, A. Alegre, E. A. Stadtmauer et al., “The eﬃcacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function,” Cancer, vol. 116, no. 16, pp. 3807– 3814, 2010. [41] R. J. D’Amato, M. S. Loughnan, E. Flynn, and J. Folkman, “Thalidomide is an inhibitor of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 4082–4085, 1994. [42] K. B. Olson, T. C. Hall, J. Horton et al., “Thalidomide in the treatment of advanced cancer,” Clinical Pharmacology & Therapeutics, vol. 6, pp. 292–297, 1965. [43] B. Barlogie, R. Desikan, P. Eddlemon et al., “Extended survival in advanced and refractory multiple myeloma after single- agent thalidomide: identiﬁcation of prognostic factors in a phase 2 study of 169 patients,” Blood, vol. 98, no. 2, pp. 492– 494, 2001.